Table 1. Characteristics of ERICH controls and ICH cases stratified by pre-ICH SSRI use.
Significance was set at p< 0.05 using chi-square and t-test’s as appropriate. Note: %, percent; APOE, apolipoprotein E allele; BMI, body mass index; ICH, intracerebral hemorrhage; n, number; SSRI, selective serotonin reuptake inhibitor; SNRI, serotonin–norepinephrine reuptake inhibitor; SARI, serotonin antagonist and reuptake inhibitors; NDRI, norepinephrine–dopamine reuptake inhibitor.
| No SSRI use (n=4830) |
SSRI use (n=352) |
Total (n=5182) |
p-value | |
|---|---|---|---|---|
| ICH, n (%) | 2141 (44.3) | 146 (41.5) | 2287 (44.1) | 0.299 |
| Lobar ICH, n (%) | 646 (19.4) | 60 (22.6) | 706 (19.6) | 0.208 |
| Non-lobar ICH, n (%) | 1495 (35.7) | 86 (29.5) | 1581 (35.3) | 0.030 |
| Age, mean (SD), years | 61.2 (14.1) | 65.6 (12.4) | 61.5 (14.0) | <0.001 |
| Female, n (%) | 1923 (39.8) | 220 (62.5) | 2143 (41.4) | <0.001 |
| BMI, mean (SD) | 29.3 (6.9) | 30.0 (7.3) | 29.4 (6.9) | 0.149 |
| Prior Stroke, n (%) | 215 (4.5) | 36 (10.2) | 251 (4.8) | <0.001 |
| Hypertension, n (%) | 3046 (63.1) | 248 (70.5) | 3294 (63.6) | 0.005 |
| Diabetes, n (%) | 1065 (22.0) | 120 (34.1) | 1185 (22.9) | <0.001 |
| High Cholesterol, n (%) | 2038 (42.2) | 232 (65.9) | 2270 (43.8) | <0.001 |
| Heart Disease, n (%) | 761 (15.8) | 89 (25.3) | 850 (16.4) | <0.001 |
| Depression, n (%) | 729 (15.1) | 262 (74.4) | 991 (19.1) | <0.001 |
| Heavy Alcohol Use, n (%) | 543 (11.2) | 22 (6.3) | 565 (10.9) | 0.004 |
| Prior Tobacco, n (%) | 2479 (51.3) | 203 (57.7) | 2682 (51.8) | 0.021 |
| Current Tobacco Use, n (%) | 904 (18.7) | 50 (14.2) | 954 (18.4) | 0.035 |
| Illicit Drug Use, n (%) | 305 (6.3) | 13 (3.7) | 318 (6.1) | 0.048 |
| Non-Aspirin Antiplatelet Use, n (%) | 204 (4.2) | 31 (8.8) | 235 (4.5) | <0.001 |
| Aspirin Use, n (%) | 1945 (40.3) | 173 (49.1) | 2118 (40.9) | 0.001 |
| Anticoagulant Use, n (%) | 270 (5.6) | 41 (11.6) | 311 (6.0) | <0.001 |
| SNRI Use, n (%) | 92 (1.9) | 4 (1.1) | 96 (1.9) | 0.302 |
| SARI Use, n (%) | 56 (1.2) | 23 (6.5) | 79 (1.5) | <0.001 |
| NDRI Use, n (%) | 33 (0.7) | 22 (6.3) | 55 (1.1) | <0.001 |
| Tricyclic Antidepressant Use, n (%) | 49 (1.0) | 8 (2.3) | 57 (1.1) | 0.029 |
| Tetracyclic Antidepressant Use, n (%) | 16 (0.3) | 4 (1.1) | 20 (0.4) | 0.019 |
| Presence of APOE e2, n (%) | 707(14.6) | 49(13.9) | 756(14.6) | 0.713 |
| Presence of APOE e4, n (%) | 1371(28.4) | 103(29.3) | 1474(28.4) | 0.725 |